Brittany Hardy

Brittany Hardy serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of critical scientific and diagnostic capabilities. She manages complex contracting actions for high-priority biomedical and laboratory infrastructure, ensuring timely delivery of equipment and services essential to infectious disease surveillance, laboratory diagnostics, and data-driven public health response. Her portfolio centers on procuring advanced analytical instruments, biological research materials, and specialized control devices that enable CDC’s national and global health operations, often under time-sensitive and mission-critical conditions. Hardy maintains strong, ongoing relationships with leading providers in the life sciences and diagnostics sectors, including General Dynamics Information Technology, Inc., GlaxoSmithKline, LLC, Cepheid, MRIGLOBAL, and the New York City Health & Hospitals Corp. These partnerships reflect a focus on proven, high-reliability vendors capable of delivering compliant, FDA-regulated, and ISO-certified products and services. Her contracting approach emphasizes technical rigor, regulatory adherence, and performance-based outcomes, fostering long-term vendor collaboration to ensure continuity of essential public health capabilities. Hardy’s procurement portfolio reflects a clear preference for full and open competition, with 100% of awards issued without set-aside designations such as 8(a), HUBZone, or SDVOSB. While socioeconomic preferences are not utilized in her contracting decisions, her focus remains on securing the highest technical quality and operational readiness, prioritizing mission-critical performance over socioeconomic categorization. Her primary procurement focus lies in NAICS 334516 (Analytical Laboratory Instrument Manufacturing), 325414 (Biological Product Manufacturing), and 334519 (Other Measuring and Controlling Device Manufacturing). She routinely acquires PCR platforms, automated sample processors, biosafety equipment, and real-time diagnostic systems used in CDC laboratories and public health response networks, demonstrating deep expertise in the technical requirements of modern infectious disease detection and biomedical research infrastructure.